Results 201 to 210 of about 1,025,996 (357)

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.

open access: yesArchives of Internal Medicine, 2000
J. Heit   +6 more
semanticscholar   +1 more source

Cryohydrocytosis: When Cold Breaks the Membrane

open access: yes
American Journal of Hematology, EarlyView.
Athina Ntoumaziou   +5 more
wiley   +1 more source

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib (PBN), a non‐covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single‐cell multi‐omic profiling (scRNA‐seq, scATAC‐seq, and scDNA‐seq) on ...
Fangfang Yan   +10 more
wiley   +1 more source

Doppler ultrasound as a screen for hepatic artery thrombosis after liver transplantation. [PDF]

open access: yes, 1986
Bowen, A   +7 more
core   +1 more source

Recurrent Genomic Alterations in BCRi‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up

open access: yes
American Journal of Hematology, EarlyView.
Jennifer A. Woyach   +16 more
wiley   +1 more source

P1682: MTHFR C677T GENOTYPE IN CORRELATION WITH THROMBOSIS AND ASSOCIATION WITH FVIII COAGULANT ACTIVITY IN GREEK PAEDIATRIC POPULATION

open access: yesHemaSphere, 2022
S. Saslis   +6 more
doaj   +1 more source

A rare cause of portal vein thrombosis: Fascioliasis. [PDF]

open access: yesRev Soc Bras Med Trop
Aydin S, Kyzy ZA, Memis KB.
europepmc   +1 more source

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo   +38 more
wiley   +1 more source

Home - About - Disclaimer - Privacy